298 related articles for article (PubMed ID: 32562778)
1. Which is the optimal timing for starting chemoprotection with gonadotropin-releasing hormone agonists after oocyte cryopreservation? Reflections on a critical case of ovarian hyperstimulation syndrome.
Marin L; Vitagliano A; Capobianco G; Dessole F; Ambrosini G; Andrisani A
J Gynecol Obstet Hum Reprod; 2021 Apr; 50(4):101815. PubMed ID: 32562778
[TBL] [Abstract][Full Text] [Related]
2. Ovarian hyper-response to administration of an GnRH-agonist without gonadotropins.
Park HT; Bae HS; Kim T; Kim SH
J Korean Med Sci; 2011 Oct; 26(10):1394-6. PubMed ID: 22022197
[TBL] [Abstract][Full Text] [Related]
3. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
[TBL] [Abstract][Full Text] [Related]
4. Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy.
Massarotti C; Stigliani S; Gazzo I; Lambertini M; Anserini P
ESMO Open; 2023 Aug; 8(4):101597. PubMed ID: 37421801
[TBL] [Abstract][Full Text] [Related]
5. Association between body mass index and oocyte maturation in patients triggered with GnRH agonist who are at high risk for severe ovarian hyperstimulation syndrome: an observational cohort study.
Lainas GT; Lainas TG; Sfontouris IA; Venetis CA; Bosdou JK; Chatzimeletiou A; Grimbizis GF; Tarlatzis BC; Kolibianakis EM
Reprod Biomed Online; 2020 Jan; 40(1):168-175. PubMed ID: 31839394
[TBL] [Abstract][Full Text] [Related]
6. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
[TBL] [Abstract][Full Text] [Related]
7. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
[TBL] [Abstract][Full Text] [Related]
8. Ovarian hyperstimulation following the sole administration of agonistic analogues of gonadotrophin releasing hormone.
Weissman A; Barash A; Shapiro H; Casper RF
Hum Reprod; 1998 Dec; 13(12):3421-4. PubMed ID: 9886527
[TBL] [Abstract][Full Text] [Related]
9. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
10. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
Orvieto R
J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
[TBL] [Abstract][Full Text] [Related]
11. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
Atkinson P; Koch J; Ledger WL
Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
[TBL] [Abstract][Full Text] [Related]
12. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Itskovitz-Eldor J; Kol S; Mannaerts B
Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
[TBL] [Abstract][Full Text] [Related]
13. Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients.
Christ J; Herndon CN; Yu B
J Assist Reprod Genet; 2021 Mar; 38(3):751-756. PubMed ID: 33471229
[TBL] [Abstract][Full Text] [Related]
14. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'.
Ling LP; Phoon JW; Lau MS; Chan JK; Viardot-Foucault V; Tan TY; Nadarajah S; Tan HH
Reprod Biomed Online; 2014 Sep; 29(3):392-4. PubMed ID: 25042608
[TBL] [Abstract][Full Text] [Related]
15. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of corifollitropin alfa/GnRH antagonist protocol combined with GnRH agonist triggering and freeze-all strategy in polycystic ovary syndrome patients.
Hwang JL; Chen SU; Chen HJ; Chen HF; Yang YS; Chang CH; Seow KM; Tzeng CR; Lin YH
J Formos Med Assoc; 2018 Jun; 117(6):535-540. PubMed ID: 28830648
[TBL] [Abstract][Full Text] [Related]
17. Suboptimal response to GnRH-agonist trigger during oocyte cryopreservation: a case series.
Russo M; Liu K; Chan C
Reprod Biol Endocrinol; 2020 Jun; 18(1):59. PubMed ID: 32503566
[TBL] [Abstract][Full Text] [Related]
18. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
[TBL] [Abstract][Full Text] [Related]
20. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
Reddy J; Turan V; Bedoschi G; Moy F; Oktay K
J Assist Reprod Genet; 2014 Jul; 31(7):927-32. PubMed ID: 24854484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
